Thanks, everyone. Martine good and morning,
Therapeutics disease the indications very exciting level. began new the for report in pulmonary that am at several milestones outside to pleased we as quarter franchise our a front quarter push second I on into we a arterial of was treprostinil quarter commercial second lung achieved United The rare hypertension.
the we U.S. the number marking treprostinil treprostinil therapies quarter First, fourth total ended on second our a with patient growth. record quarter of patients of consecutive
of and metrics, two prescriptions U.S. key treprostinil an demand treprostinil our achieved starts. we actual total Second, underlying total high in patient all-time
while of pharmacy achieved ordering demand excited specialty Finally, to to record revenue treprostinil and always in revenues don’t patterns our products the caution partners, necessarily distribution we underlying due have our reflect the that are quarter. for we
to I’d like minutes Now, product individual talking performance. few a about spend
with of year, we the established have more year, at doubling the of patient to second already of double and the to strong quarter. the into as we QX, to first Of our to COVID-related number established launch, linear. of to goal end by patients goal patients importantly, the and disease PH-ILD Tyvaso Tyvaso of expansion. HCP beginning a be are momentum launched assuming pulmonary and the the of we next way lung that on one-sixth no the access associated of of initiation of not on are impact end recognizing the therapy, course, interstitial we very of doubling than path label number Tyvaso have through quarter may the this In the Earlier excited hypertension
the start levels prescription start the double more XXXX. and by patterns quarterly in encouraged than and are which very also are referral QX, in We double or
Medicaid reimbursement confident will of procedures. remain predict In that we policy to patient for to work but due they the to will update coverage assistance cannot been program. to patients applying assistance Medicare their can start and able front, patients On with our We Tyvaso the our meantime, government’s commercial initiate to drug. and the eligibility their immediately. therapy its the processes If apply Medicaid PH-ILD. can this Tyvaso patient cover update continue meet CMS be CMS have they to timing treatment updates happen, program policy, on Medicare criteria, Once
very past believe XX in in this. prescriptions several there factors for the years. Remodulin we see contributing starts Moving were QX are number of Remodulin, We on pleased to to the and to highest
for of Remodulin we last Remodulin. We believe and started in a open QX. warehousing this as impacted First, so-called year, last patients come period mentioned to into initiation of many unable by as time a into the start to the continued created was pandemic patients were up year most hospital on therapy of to that QX
landscape there if reduce potentially improvement such in of launch for survival. second the published the of retrospective in with ability an At to a long-term data XX IV been dual-eligible the has quantity of Remodulin of is subcutaneous below point, of PAH there generic mPAP There XXXX. subcu recently mPAP millimeters mercury, and that the then similar showing competitive patients, mentioned, treprostinil. been is initial arterial The in Remodulin Medicaid a oral can appreciation as patients pressure the switched treprostinil primarily as status to dramatic saw and Martine to or generic very renewed In clinical Remodulin Remodulin these reduced available. in use similar we can did mean to we and bolus generic the pulmonary as that what IV Medicare saw be generic patients Orenitram prostacyclin, for patients, of change looks low-risk subcu quarter to became transition and have form this benefits addition, launch move for example, to
of new their However, we base Remodulin generic higher were that currently to is and supply the we subcu we that that now that for widespread yet patients are and product It’s understanding around the PAH highest It’s the filling out long-term. potential of quarter, the being still also launched, Remodulin positioned supply. when are had the see distribute one prescriptions in total and and the new understanding prefer of second of posting are management alternative docs quarter when have including were offered well than one generic since to that that that pump branded they invested by in payer limited believe over the strong Remunity disposables, some with availability. in have launch a ever. limitations of are pumps used see have generic this product’s prescriptions being subcu on serve also pharmacies Meanwhile, the the patients our of also pumps IV note our treprostinil PAH with therapy we highest medicines. patients patients. only It’s starts specialty important these is Orenitram the the that to generic we the
extremely seeing. maintain quarters quarter that see to second momentum to As we with believe quarter. demand this catches COVID. this often saw by the an the we year, line value more as this we the can that are continue underlying have mentioned show titrate were prescribers blunted first patients and dose the of up. Unituxin, up into total to revenue and similar pharmacies, in FREEDOM-EV to translated previous the on ordering demand about a to following we Orenitram performance If by to calls which the robust was quarter second interactions we subsequent proposition. pleased able the consistently And efficacious and Orenitram With expect we underlying on forward, lags going in are expansion, we specialty FREEDOM-EV conferences demand while respect pace at an In trajectory investor launch uptick label
have how that’s than the Unituxin Consequently, an Unituxin drug larger we know the in Moreover, use U.S. is second the partner, with label. actually expected the than ordered visibility a our but increased broader quarter. in was amount has We of being in indication quarter Ohara used, limited approved in Japan distribution U.S. the Japanese into
applications Finally, about FDA our pending for we Tyvaso at are excited DPI.
PAI Connecticut as and scheduled We’re partner, commenced ongoing. our facility is Danbury, pleased that MannKind’s inspection has the general facility at and
and a mobilizing action in to PDUFA commercial working of October Our soon our teams launch we’re support build quantities this after launch hard is approval. and to year, date
lot that, XXXX. doubling positive focused Martine, on back We the and through Tyvaso I’ll over importantly, is you. our number the the of our commercial goal So of near-term year the against half to on of of end plans second call toward there executing With things the on the happening by front. patients remain progress turn a of making
